Lorimer I A, Keppler-Hafkemeyer A, Beers R A, Pegram C N, Bigner D D, Pastan I
Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4255, USA.
Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14815-20. doi: 10.1073/pnas.93.25.14815.
EGFRvIII is a mutant epidermal growth factor receptor found in glioblastoma, and in carcinoma of the breast, ovary, and lung. The mutant receptor has a deletion in its extracellular domain that results in the formation of a new, tumor-specific extracellular sequence. Mice were immunized with a synthetic peptide corresponding to this sequence and purified EGFRvIII. A single chain antibody variable domain (scFv) phage display library of 8 x 10(6) members was made from the spleen of one immunized mouse. A scFv specific for EGFRvIII was isolated from this library by panning with successively decreasing amounts of synthetic peptide. This was used to make an immunotoxin by fusing the scFv DNA sequence to sequences coding for domains II and III of Pseudomonas exotoxin A. Purified immunotoxin had a Kd of 22 nM for peptide and a Kd of 11 nM for cell-surface EGFRvIII. The immunotoxin was very cytotoxic to cells expressing EGFRvIII, with an IC50 of 1 ng/ml (16 pM) on mouse fibroblasts transfected with EGFRvIII and an IC50 of 7-10 ng/ml (110-160 pM) on transfected glioblastoma cells. There was no cytotoxic activity at 1000 ng/ml on the untransfected parent glioblastoma cell line. The immunotoxin was completely stable upon incubation at 37 degrees C for 24 h in human serum. The combination of good affinity, cytotoxicity and stability make this immunotoxin a candidate for further preclinical evaluation.
表皮生长因子受体变体III(EGFRvIII)是一种在胶质母细胞瘤以及乳腺癌、卵巢癌和肺癌中发现的突变型表皮生长因子受体。该突变受体的细胞外结构域存在缺失,导致形成一个新的、肿瘤特异性的细胞外序列。用与该序列对应的合成肽和纯化的EGFRvIII对小鼠进行免疫。从一只免疫小鼠的脾脏构建了一个含有8×10⁶个成员的单链抗体可变区(scFv)噬菌体展示文库。通过用逐渐减少量的合成肽进行淘选,从该文库中分离出对EGFRvIII具有特异性的scFv。通过将scFv DNA序列与编码铜绿假单胞菌外毒素A结构域II和III的序列融合,以此制备一种免疫毒素。纯化后的免疫毒素对肽的解离常数(Kd)为22 nM,对细胞表面EGFRvIII的Kd为11 nM。该免疫毒素对表达EGFRvIII的细胞具有很强的细胞毒性,对转染了EGFRvIII的小鼠成纤维细胞的半数抑制浓度(IC50)为1 ng/ml(16 pM),对转染的胶质母细胞瘤细胞的IC50为7 - 10 ng/ml(110 - 160 pM)。在未转染的亲本胶质母细胞瘤细胞系中,1000 ng/ml时没有细胞毒性活性。该免疫毒素在人血清中于37℃孵育24小时后完全稳定。良好的亲和力、细胞毒性和稳定性相结合,使得这种免疫毒素成为进一步临床前评估的候选物。